COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 studyc19mp.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.89Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]0/1401/62Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 mortality resultc19mp.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.89Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Fischer (RCT)-33%1.33 [0.14-12.5]hosp.3/1401/62Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment-33%1.33 [0.14-12.5]3/1401/62-33% improvementAll studies-33%1.33 [0.14-12.5]3/1401/62-33% improvement1 molnupiravir COVID-19 hospitalization resultc19mp.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.25Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 serious outcomesc19mp.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.89Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Fischer (RCT)49%0.51 [0.22-1.18]10/1189/54Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment49%0.51 [0.22-1.18]10/1189/5449% improvementAll studies49%0.51 [0.22-1.18]10/1189/5449% improvement1 molnupiravir COVID-19 viral clearance resultc19mp.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.58Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 Randomized Controlled Trialsc19mp.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.89Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]0/1401/62Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 RCT mortality resultc19mp.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.89Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlFischer (RCT)65%0.35 [0.01-8.33]death0/551/62Fischer (RCT)67%0.33 [0.01-8.03]death0/621/62Fischer (RCT)58%0.42 [0.02-10.0]death0/231/62Fischer (RCT)-33%1.33 [0.14-12.5]hosp.3/1401/62Fischer (RCT)-13%1.13 [0.07-17.6]hosp.1/551/62Fischer (RCT)-100%2.00 [0.19-21.5]hosp.2/621/62Fischer (RCT)58%0.42 [0.02-10.0]hosp.0/231/62Fischer (RCT)49%0.51 [0.22-1.18]viral+10/1189/54Fischer (RCT)89%0.11 [0.01-0.86]viral+1/539/54Fischer (RCT)30%0.70 [0.25-1.93]viral+5/439/54Fischer (RCT)-9%1.09 [0.37-3.18]viral+4/229/54Fischer (RCT)92%0.08 [0.01-0.62]viral+1/1176/54Fischer (RCT)92%0.08 [0.00-1.34]viral+0/536/54Fischer (RCT)91%0.09 [0.00-1.48]viral+0/426/54Fischer (RCT)59%0.41 [0.05-3.20]viral+1/226/54Fischer (RCT)30%0.70 [0.37-1.36]viral+19/13712/61Fischer (RCT)62%0.38 [0.13-1.12]viral+4/5312/61Fischer (RCT)-8%1.08 [0.54-2.18]viral+13/6112/61Fischer (RCT)56%0.44 [0.11-1.83]viral+2/2312/61molnupiravir COVID-19 outcomesc19mp.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home